Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.64 |
| ▸ | LTA4H | P09960 | 7/20 | 0.60 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157301 | 0.90 | LTA4H (0.55) | KCNH2LTA4HKCNA5 | |
| SCHEMBL1332050 | 0.87 | KCNH2 (0.64) | KCNH2LTA4HKCNA5 | |
| SCHEMBL2158413 | 0.87 | KCNH2 (0.67) | KCNH2 | |
| SCHEMBL2157359 | 0.86 | KCNH2 (0.61) | KCNH2LTA4HKCNA5HRH3 | |
| SCHEMBL1332740 | 0.85 | L3MBTL1 (0.65) | KCNH2LTA4HDRD3 | |
| SCHEMBL1334087 | 0.84 | LTA4H (0.71) | KCNH2LTA4HHRH3 | |
| SCHEMBL1334161 | 0.83 | KCNH2 (0.66) | KCNH2LTA4HHRH3DRD3 | |
| Hydrochloric Acid SCHEMBL1334253 | 0.83 | KCNH2 (0.73) | KCNH2LTA4HHRH3 | |
| SCHEMBL1334145 | 0.82 | SIGMAR1 (0.71) | KCNH2LTA4HKCNA5HRH3DRD3 | |
| SCHEMBL1334388 | 0.82 | ALDH1A1 (0.54) | KCNH2LTA4HKCNA5HRH3DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183374-B2 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| EP-1978959-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2011-11-09 | — | — | EP | disclosed |
| EP-2340835-A1 | Piperidine and piperazine derivatives | M's Science Corporation (JP) | 2011-07-06 | — | — | EP | disclosed |
| EP-1976525-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | AGY THERAPEUTICS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SUN CONNIE L | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SIGMAR1, OPRM1, OPRD1 | KCNH2 332/4885LTA4H 2934/4885KCNA5 273/4885 |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | SIGMAR1, OPRM1, OPRD1 | KCNH2 360/4885LTA4H 3616/4885KCNA5 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.